Skip to main content

Hansa Biopharma

Hansa Biopharma AB is a commercial-stage biopharmaceutical enterprise headquartered in Lund, Sweden. The company focuses on the development and commercialization of immunomodulatory enzymes for rare immunological diseases and transplant medicine. Its proprietary core technology centers on Imlifidase, an enzyme designed to cleave immunoglobulin G antibodies to enable successful organ transplantation in highly sensitized patients. Principal revenue is derived through commercial pharmaceutical sales of its approved treatments, medical grants, and biopharmaceutical research collaborations. The enterprise serves transplant centers, specialized clinicians, and patients globally. Hansa Biopharma AB is publicly listed on Nasdaq Stockholm.

4 of the funds FundTelligence covers report a position in Hansa Biopharma.

Legal name
Hansa Biopharma AB
Sector
Health Care
Country
Sweden
Funds holding it
4

Funds holding Hansa Biopharma

Loading...